BC
DNLI icon

Bayforest Capital’s Denali Therapeutics DNLI Stock Holding History

Bayforest Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
11,437
+11,370
+16,970% +$234K 0.27% 73
2026
Q1 		$1.29K Sell
67
-20,366
-100% -$405K ﹤0.01% 855
2025
Q4 		$337K Buy
+20,433
New +$345K 0.25% 96

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's DNLI Position: Q2 2026 in Review

Bayforest Capital increased its Denali Therapeutics (DNLI) stake by 16,970% in Q2 2026, buying an estimated $234K and bringing the position to 11,437 shares worth $294K. The position accounts for 0.27% of the portfolio, ranked #73.

Bayforest Capital first reported a position in DNLI in Q4 2025 and has held it in 3 quarters since. The position peaked at $337K in Q4 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Bayforest Capital held 11,437 shares of Denali Therapeutics worth $294K as of Q2 2026.
  • Bayforest Capital bought 11,370 Denali Therapeutics shares in Q2 2026, an estimated $234K.
  • Denali Therapeutics made up 0.27% of Bayforest Capital's portfolio in Q2 2026, its #73 holding.
  • Bayforest Capital first reported a position in Denali Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Bayforest Capital's Denali Therapeutics position peaked at $337K in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.